Fig. 3

Adjusted odds ratios for association between NOAC (reference to warfarin) and risk of bleeding hospitalisation, CVD hospitalisation, CVD re-hospitalisation. Naive model weighted for age at incident anticoagulant prescription, gender, the CCG where their practices belong to, and duration of having recorded diagnosed type 2 diabetes by their incident anticoagulant prescription; model (i) weighted for all adjusted variables in model naïve model plus body mass index, systolic blood pressure, HbA1c and total cholesterol; model (ii) weighted for all adjusted variables in model (i) plus prior bleeding (gastrointestinal bleeding and other bleeding) and cardiovascular disease subtypes (hypertension, atrial fibrillation, heart failure, ischemic heart disease, cerebrovascular diseases, valvular heart disease, venous thrombosis); model (iii) weighted for all adjusted variables in model (ii) plus prescriptions potentially relevant to bleeding event (antidepressant, Statin, NSAIDS, Corticosteroid, proton pump inhibitor for gastrointestinal disease, and antiplatelet); model (iv) weighted for all adjusted variables in model (iii) plus anti-hypertensive treatment (diuretics, alpha-blocker, calcium channel blocker, ARB/ACE); model (v) weighted for all adjusted variables in model (iv) plus anti-diabetes treatments (insulin, metformin, sulfonylurea, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide 1)